BR112021022503A2 - Métodos de administração de anticorpo anti-cd38 para tratar mieloma múltiplo - Google Patents

Métodos de administração de anticorpo anti-cd38 para tratar mieloma múltiplo

Info

Publication number
BR112021022503A2
BR112021022503A2 BR112021022503A BR112021022503A BR112021022503A2 BR 112021022503 A2 BR112021022503 A2 BR 112021022503A2 BR 112021022503 A BR112021022503 A BR 112021022503A BR 112021022503 A BR112021022503 A BR 112021022503A BR 112021022503 A2 BR112021022503 A2 BR 112021022503A2
Authority
BR
Brazil
Prior art keywords
multiple myeloma
antibody
treat multiple
administration methods
antibody administration
Prior art date
Application number
BR112021022503A
Other languages
English (en)
Portuguese (pt)
Inventor
Campana Zambrano Frank
Heloise Audat
Sylvia Marion
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of BR112021022503A2 publication Critical patent/BR112021022503A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/804—Blood cells [leukemia, lymphoma]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
BR112021022503A 2019-05-14 2020-05-13 Métodos de administração de anticorpo anti-cd38 para tratar mieloma múltiplo BR112021022503A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962847825P 2019-05-14 2019-05-14
US201962860739P 2019-06-12 2019-06-12
US201962899088P 2019-09-11 2019-09-11
EP20305223 2020-03-03
PCT/US2020/032754 WO2020232173A1 (en) 2019-05-14 2020-05-13 Methods of administering anti-cd38 antibody to treat multiple myeloma

Publications (1)

Publication Number Publication Date
BR112021022503A2 true BR112021022503A2 (pt) 2021-12-28

Family

ID=71094805

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021022503A BR112021022503A2 (pt) 2019-05-14 2020-05-13 Métodos de administração de anticorpo anti-cd38 para tratar mieloma múltiplo

Country Status (15)

Country Link
US (1) US20210171650A1 (cg-RX-API-DMAC7.html)
EP (1) EP3969004A1 (cg-RX-API-DMAC7.html)
JP (2) JP7801132B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220008305A (cg-RX-API-DMAC7.html)
CN (2) CN120501855A (cg-RX-API-DMAC7.html)
AU (1) AU2020274169A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021022503A2 (cg-RX-API-DMAC7.html)
CA (1) CA3140034A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021016606A2 (cg-RX-API-DMAC7.html)
IL (1) IL287832A (cg-RX-API-DMAC7.html)
MA (1) MA55967A (cg-RX-API-DMAC7.html)
MX (1) MX2021013910A (cg-RX-API-DMAC7.html)
SG (1) SG11202112513YA (cg-RX-API-DMAC7.html)
TW (1) TW202108624A (cg-RX-API-DMAC7.html)
WO (1) WO2020232173A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA45674A (fr) 2016-07-15 2019-05-22 Takeda Pharmaceuticals Co Méthodes et matériaux permettant d'évaluer une réponse à des traitements de déplétion de plasmoblastes et de plasmocytes
MX2020007429A (es) 2018-01-12 2020-10-15 Takeda Pharmaceuticals Co Dosificacion subcutanea de anticuerpos anti grupo de diferenciacion 38 (cd38).
BR112021000065A2 (pt) * 2018-07-10 2021-04-06 Sanofi Terapias de combinação contra câncer direcionando cd38 e tgf-beta
WO2020250033A1 (en) * 2019-06-10 2020-12-17 Takeda Pharmaceutical Company Limited Combination therapies using cd-38 antibodies
IL302640A (en) * 2020-11-03 2023-07-01 Sanofi Aventis Us Llc Use of isatuximab for the treatment of multiple myeloma
KR20240024047A (ko) 2021-04-08 2024-02-23 아티바 바이오테라퓨틱스, 인크. Nk 세포와 cd38 표적 항체를 이용한 암 치료 방법

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
US10342869B2 (en) * 2012-12-07 2019-07-09 The Regents Of The University Of California Compositions comprising anti-CD38 antibodies and lenalidomide
EP3313441B1 (en) * 2015-06-24 2024-02-21 Janssen Biotech, Inc. Immune modulation and treatment of solid tumors with antibodies that specifically bind cd38
IL285110B2 (en) * 2019-01-28 2025-11-01 Sanofi Sa Methods of treating multiple myeloma

Also Published As

Publication number Publication date
JP7801132B2 (ja) 2026-01-16
WO2020232173A1 (en) 2020-11-19
US20210171650A1 (en) 2021-06-10
TW202108624A (zh) 2021-03-01
EP3969004A1 (en) 2022-03-23
CN120501855A (zh) 2025-08-19
MA55967A (fr) 2022-03-23
CO2021016606A2 (es) 2022-04-29
CA3140034A1 (en) 2020-11-19
AU2020274169A1 (en) 2022-01-20
JP2025166108A (ja) 2025-11-05
SG11202112513YA (en) 2021-12-30
JP2022532356A (ja) 2022-07-14
IL287832A (en) 2022-01-01
CN114080233A (zh) 2022-02-22
MX2021013910A (es) 2022-03-11
KR20220008305A (ko) 2022-01-20

Similar Documents

Publication Publication Date Title
MX2023012450A (es) Esketamina para el tratamiento de la depresion.
EP4487908A3 (en) Methods of treating crohn's disease and ulcerative colitis
MY201603A (en) Combination of dextromethorphan and bupropion for treating depression
CO2021016606A2 (es) Métodos para administrar un anticuerpo anti-cd38 para tratar el mieloma múltiple
FI3773715T3 (fi) Mirikitsumabi haavaisen paksusuolitulehduksen hoitamisessa
PH12020551425A1 (en) Rimegepant for cgrp related disorders
BR112015029918A2 (pt) uso de alta dose de pridopidina para tratar a doença de huntington
BRPI0513200A (pt) uso de um anticorpo anti-igf-1r na preparação de um medicamento para tratamento combinado para malignidades não-hematológicas
BR112023006337A2 (pt) Produto farmacêutico, uso de um conjugado anticorpo anti-her2-fármaco ou um inibidor seletivo de parp1, e, método de tratamento do câncer
RU2015134581A (ru) Доноры нитроксила с улучшенным терапевтическим индексом
BR112017006272A2 (pt) composição farmacêutica para tratar colite ulcerativa.
AR104771A1 (es) Inhalador de polvo seco
NO20055880L (no) Memantin orale doseringsformer
RU2016149316A (ru) Лечение ревматоидного артрита
FI3359572T3 (fi) Menetelmä multippeliskleroosin hoitamiseksi
WO2017142871A8 (en) Methods comprising fixed intermittent dosing of cediranib
MX2023014898A (es) Terapia combinada anti-vhc ventajosa.
WO2014193269A4 (ru) Лекарственное средство на основе дииндолилметана и его применение для лечения гриппа и респираторных вирусных инфекций
BR112022000734A2 (pt) Método para tratar câncer em um paciente, uso de composto 1, e, composto 1
MX2021007324A (es) Terapia oral con acido 6,8-bis-benciltio-octanoico.
AR102903A1 (es) Inhalador de polvo seco
EP4241838A3 (en) Use of ribose for treatment of subjects having congestive heart failure
NZ781127A (en) Mirikizumab for use in a method of treating crohn’s disease
Iida Hypersensitivity: case report
PL431290A1 (pl) Bezpieczna metoda podawania substancji ślimakom w formie iniekcji dożylnych